Overview

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

Status:
Active, not recruiting

Trial end date:
2021-09-28

Target enrollment:

Participant gender:

Summary

This phase II trial studies the side effects of erlotinib hydrochloride (350 mg po once weekly for up to 6 months) and how well it works in reducing duodenal polyp burden in patients with familial adenomatous polyposis at risk of developing colon cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Erlotinib Hydrochloride